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Introduction
============

Surgical site infections after cardiac operations or total joint arthroplasties are associated with severe outcomes, including important increases in hospital length of stay, readmission rates, healthcare costs, and mortality rates.[@ref1] [@ref2] [@ref3] Many such infections are thought to be preventable. Consequently, the US Centers for Medicare and Medicaid Services no longer reimburse hospitals for some surgical site infections, including mediastinitis, which per patient can cost over \$40 000 (£25 800; €30 700).[@ref4] [@ref5] The high costs of these infections are also detrimental to publicly funded healthcare systems, such as the UK's National Health Service. Additionally, in this era of mandatory reporting, hospitals may soon be required to report rates of surgical site infections publicly, which could lead to more financial repercussions if patients or insurers choose institutions with lower infection rates. Therefore, implementation of an evidence based bundle of interventions to decrease surgical site infections could benefit both patients and hospitals.

The Surgical Care Improvement Project measures recommend preoperative prophylaxis with a β lactam antibiotic for cardiac and orthopedic procedures, unless the patient is known to be at high risk for methicillin (meticillin) resistant *Staphylococcus aureus* (MRSA) infection or the hospital has a high rate of MRSA related surgical site infections. In those cases, glycopeptide antibiotics such as vancomycin are recommended.[@ref6] [@ref7] Yet, in the wake of extensive publicity about MRSA, many hospitals have implemented additional interventions to prevent surgical site infections with Gram positive bacteria---particularly MRSA---such as providing vancomycin prophylaxis for all surgical patients or decolonizing patients using nasal mupirocin to prevent transmission of *S aureus* from the nose to the surgical site.[@ref8] [@ref9] However, despite guidelines and numerous studies dealing with the effectiveness of these interventions, researchers and clinicians have not reached consensus on how to optimally prevent Gram positive surgical site infections,and practices are often inconsistent both within and across hospitals.[@ref6] [@ref9] [@ref10] [@ref11] [@ref12]

Recently, bundled interventions have greatly decreased the rates of specific healthcare associated infections such as central line related bloodstream infections and MRSA infections.[@ref13] [@ref14] A bundled intervention that goes beyond measures advocated by the Surgical Care Improvement Project and includes nasal decolonization and glycopeptide prophylaxis could potentially reduce rates of Gram positive surgical site infections, specifically those associated with *S aureus*. An assessment of the effectiveness of this bundled intervention and the individual components of the bundle could greatly inform clinical practice.

We systematically reviewed and evaluated all studies that assessed the effectiveness of a bundle that included both nasal decolonization and glycopeptide prophylaxis and studies that assessed individual components of the bundle, for preventing Gram positive surgical site infections among patients who underwent cardiac operations or total joint arthroplasties. We also evaluated the effectiveness of these interventions for preventing Gram positive surgical site infections caused by either MRSA or methicillin susceptible *S aureus* (MSSA) surgical site infections. We hypothesized that a bundle that included nasal decolonization and glycopeptide prophylaxis would result in a lower incidence of Gram positive surgical site infections compared with standard care.

Methods
=======

Search strategy
---------------

These meta-analyses were conducted according to the MOOSE and PRISMA checklists.[@ref15] [@ref16] We included all research studies that assessed nasal decolonization or glycopeptide prophylaxis, or both for the prevention of surgical site infections with Gram positive bacteria. We decided a priori to include both randomized controlled trials and observational studies (for example, quasi-experimental studies) because randomized controlled trials of bundles to prevent infections often are thought not to be logical because numerous sites are necessary for a cluster randomized trial and the trial would be prohibitively expensive.[@ref17]

Guided by a librarian we identified potentially relevant studies through a structured literature review. Three authors (JK, JC, MS) searched the PubMed databases, the Cochrane database of systematic reviews, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, and clinicaltrials.gov for articles published from 1 January 1995 through 31 January 2012, with keywords and medical subject heading (MeSH) terms "surgical wound infection" AND "screening" or "surveillance" or "prophylactic" or "prophylaxis" or "antimicrobial" or "antibiotic" AND "cardiac" or "orthopedic". We also hand searched journals recommended by a technical expert panel of surgeons and infectious disease physicians: *Infection Control and Hospital Epidemiology, Clinical Infectious Diseases, Journal of Hospital Infection, American Journal of Infection Control, Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, American Journal of Respiratory and Critical Care Medicine, Proceedings of the American Thoracic Society, Journal of Arthroplasty*, and *Journal of Bone & Joint Surgery*.

We reviewed the reference lists of retrieved articles to identify studies that were not obtained from the preliminary literature searches. To find abstracts of unpublished studies we then reviewed proceedings from conferences that were recommended by the technical expert panel: the Interscience Conference on Antimicrobial Agents and Chemotherapy, the Society for Healthcare Epidemiology of America annual meeting, the American Academy of Orthopaedic Surgeons annual meeting, and the American Thoracic Society annual meeting. If an abstract or article did not provide sufficient information to be included in the meta-analyses (for example, the number of Gram positive surgical site infections), the current investigators contacted the study's authors for the necessary information.

Inclusion and exclusion criteria
--------------------------------

Studies were included if they met the following criteria: published in English, assessed Gram positive surgical site infections as an outcome, included a comparison group, and patient populations concerned adults who underwent cardiac procedures, total joint arthroplasty, or general orthopedic procedures.

We excluded studies if they were case reports, commentaries, guidelines, editorials, animal studies, risk factor studies, studies that did not include an intervention, or pediatric studies. Additionally we excluded studies if they assessed antimicrobial agents for the treatment of surgical site infections, had insufficient data, or were mathematical modeling studies.

Outcomes of interest
--------------------

The primary outcome of interest was surgical site infections caused by Gram positive bacteria. Secondary outcomes of interest included surgical site infections caused by a specific Gram positive organism---S*aureus*, including methicillin (meticillin) resistant *S aureus* (MRSA) and methicillin susceptible *S aureus* (MSSA). We chose surgical site infections caused by *S aureus* as secondary outcomes for two reasons. Firstly, many studies utilize the interventions of interest---decolonization and glycopeptide prophylaxis---to prevent *S aureus* surgical site infections specifically. Secondly, *S aureus* is the most common cause of surgical site infections, thus it is important to evaluate such infections alone.[@ref18] Additionally, to perform a preliminary evaluation of whether interventions focused on reducing the risk of *S aureus* surgical site infections might increase the risk of surgical site infections caused by other pathogens, we also assessed the association between the interventions of interest and all surgical site infections and those caused by Gram negative bacteria. However, we did not include the latter outcomes in our systematic literature review or inclusion and exclusion criteria.

Data extraction and risk of bias assessment
-------------------------------------------

We screened the titles and abstracts from 1423 articles to assess whether they met the inclusion or exclusion criteria. If the screeners could not determine whether the study was relevant, two investigators reviewed the article in detail. Two of the three independent reviewers (LH, MS, EP) abstracted data for each article and a third party (MF) compared the two sets of data for agreement. The first author reviewed all inconsistent assessments and the three independent reviewers resolved their disagreements by consensus.

The three independent reviewers abstracted data from the study papers on year of publication, study design, type of surgical procedure assessed, intervention assessed, outcomes assessed, method of measuring the outcome (for example, by whom, definition of surgical site infections), inclusion and exclusion criteria for each study, and the associations between interventions and surgical site infection rates. The reviewers also determined whether a bundled approach was used. They reviewed articles that assessed nasal decolonization as an intervention to determine the patient population decolonized (for example, all patients, only *S aureus* carriers, only MRSA carriers), antimicrobial used (for example, mupirocin, chlorhexidine gluconate), and the dosing regimen. The reviewers also read articles that assessed preoperative prophylaxis using glycopeptides to identify which glycopeptide was used (for example, vancomycin, teicoplanin), and which antimicrobial agent (for example, cefazolin) served as the comparator.

The investigators used the Cochrane risk of bias tool to assess randomized controlled trials,[@ref19] and the Downs and Black scoring system to assess the risk of bias in the observational studies.[@ref20] The Downs and Black scoring system is applicable for both cohort studies and before and after quasi-experimental studies. We evaluated each study using the subscales in the Downs and Black tool that assessed reporting, external validity, internal validity-bias, internal validity-confounding, and power. Both scoring systems are valid and reliable and have been widely used by other investigators.

Statistical analysis
--------------------

Using the extracted raw data, we calculated the natural log of the relative risk and variance.[@ref21] None of the studies included in our review adjusted statistically for potential confounders. Thus we only included raw data in the analyses. Pooled relative risk estimates from random effect models are presented.[@ref21] [@ref22] In addition, we performed sensitivity analyses in which we used fixed effect models to determine both pooled relative risk estimates and pooled risk difference estimates.

We used Microsoft Excel 2007 and the Cochrane Review Manager (RevMan) version 5.1.[@ref23] To assess heterogeneity, we used the Cochran Q statistic, the I^2^ statistic, and the results of stratified analyses based on the following a priori categories: organism causing the surgical site infections (all *S aureus*, MRSA only, MSSA only), patient population decolonized (all patients, *S aureus* carriers, MRSA carriers), and study design (randomised controlled trial versus quasi-experimental study). We visually inspected funnel plots for symmetry to evaluate possible publication bias.

Results
=======

Figure 1[](#fig1){ref-type="fig"} summarises the search and review process. Among the 74 articles reviewed in detail, 39 studies on independent populations reported data that contributed to the meta-analyses. Among the 39 studies that met the inclusion criteria, 17 assessed the effectiveness of nasal decolonization compared with standard of care,[@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] 15 compared glycopeptide prophylaxis with β lactam prophylaxis,[@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] and seven assessed a bundle in which patients were screened for nasal colonization with *S aureus*, decolonized, and MRSA carriers given glycopeptide prophylaxis and all other surgical patients given β lactam prophylaxis.[@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] Of the 15 study authors who we attempted to contact, 12 responded. Three authors did not have the necessary data, but nine shared their data.

![**Fig 1** Literature search for articles on nasal decolonization or glycopeptide prophylaxis for preventing surgical site infections (SSIs) caused by Gram positive bacteria](schm011382.f1_default){#fig1}

Of the 39 studies included in the meta-analysis, 13 were randomized controlled trials and 26 were observational studies. Thirty six of these studies were published in peer reviewed journals, whereas three were presented in abstract form only (see supplementary table 1). Overall, the randomized controlled trials included in this meta-analysis had a fairly low risk of bias (fig 2[](#fig2){ref-type="fig"}). Table 1[](#tbl1){ref-type="table"} presents the Downs and Black subscale scores for each observational study. In general, the observational studies had good external validity but poor internal validity.

###### 

 Risk of bias among observational studies as measured by Downs and Black subscales. Values in brackets are total scores achievable

  Studies by intervention             Reporting (11)   External Validity (3)   Internal validity-bias (7)   Internal validity-confounding (6)   Sufficiently powered?
  ----------------------------------- ---------------- ----------------------- ---------------------------- ----------------------------------- -----------------------
  Decolonization studies:                                                                                                                       
   Cimochowski 2001^29^               9                3                       3                            1                                   Yes
   Coskun 2005^30^                    5                3                       2                            1                                   No
   Graf 2009^31^                      7                3                       1                            1                                   Yes
   Kluytmans 1996^32^                 8                3                       3                            1                                   Yes
   Martorell 2004^33^                 6                3                       3                            1                                   Yes
   Nicholson 2006^34^                 7                3                       2                            1                                   Yes
   Coskun 2004^35^                    7                3                       2                            1                                   Yes
   Gernaat-van der Sluis 1998^36^     10               3                       4                            1                                   No
   Price 2008^37^                     8                3                       3                            2                                   No
   Hacek 2009^38^                     8                3                       2                            1                                   Yes
   Sankar 2005^40^                    6                3                       1                            1                                   No
   Wilcox 2003^39^                    7                3                       3                            1                                   Yes
  Glycopeptide prophylaxis studies:                                                                                                             
   Pear 1998^50^                      9                3                       3                            1                                   No
   Spelman 2002^51^                   9                3                       4                            1                                   Yes
   Bull 2010^52^                      6                3                       2                            2                                   No
   Gupta 2011^53^                     8                3                       3                            2                                   No
   Merrer 2006^42^                    8                3                       3                            2                                   No
   Sewick 2012^54^                    10               3                       4                            3                                   No
   Soriano 2006^55^                   9                3                       2                            1                                   Yes
  Bundle studies:                                                                                                                               
   Jog 2008^56^                       6                3                       3                            1                                   No
   Walsh 2011^57^                     7                3                       3                            2                                   Yes
   Kim 2010^58^                       8                3                       4                            1                                   Yes
   Sporer 2011^59^                    5                3                       1                            1                                   No
   Acebedo 2009^60^                   7                3                       1                            1                                   No
   Rao 2011^61^                       7                3                       3                            2                                   Yes
   Hadley 2010^62^                    6                3                       3                            2                                   No

![**Fig 2** Risk of bias assessment for randomized controlled trials. + indicates low risk of bias, − indicates high risk of bias, and ? indicates unclear risk of bias](schm011382.f2_default){#fig2}

Bundle including decolonization and glycopeptide prophylaxis meta-analysis
--------------------------------------------------------------------------

Seven quasi-experimental studies assessed infection prevention bundles that utilized both nasal decolonization and glycopeptide prophylaxis. Two studies decolonized MRSA carriers only, two decolonized MRSA carriers and MSSA carriers, and three decolonized all patients in the intervention group; in one of the latter studies, mupirocin treatment was stopped if the results of nares cultures were negative. MRSA carriers received vancomycin for prophylaxis in four studies, vancomycin and cefazolin in two studies, and teicoplanin in one study (see supplementary table 1a). Two of these studies included cardiac operations, three included total joint arthroplasties, and two included general orthopedic surgical procedures (see supplementary table 1a). All of these studies were sufficiently homogeneous and thus could be included in the meta-analyses to assess all outcomes (I^2^=0%, P\>0.30).

In this meta-analysis, the decolonization and prophylaxis bundle was significantly protective against surgical site infections caused by both Gram positive bacteria (fig 3[](#fig3){ref-type="fig"}) and *S aureus* (table 2[](#tbl2){ref-type="table"}). Although this bundle was shown to be significantly protective against MRSA and MSSA surgical site infections, the effect estimate for MRSA surgical site infections was stronger than for MSSA surgical site infections, possibly because glycopeptide prophylaxis was used to prevent the MRSA surgical site infections (table 2).

###### 

 Stratified analyses

  Studies by intervention             Pooled relative risk (95% CI)                                                                                               
  ----------------------------------- ------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------
  Decolonization studies:                                                                                                                                         
   Gram positive SSIs                 0.41 (0.30 to 0.55)†            0.46 (0.32 to 0.67)†   0.32 (0.22 to 0.47)    0.41 (0.30 to 0.55)†   0.63 (0.36 to 1.13)†   0.35 (0.27 to 0.46)
   *Staphylococcus aureus* SSIs       0.39 (0.31 to 0.50)             0.45 (0.34 to 0.58)    0.32 (0.21 to 0.47)    0.39 (0.31 to 0.50)    0.46 (0.29 to 0.73)    0.37 (0.28 to 0.49)
   MRSA SSIs                          0.30 (0.15 to 0.62)†            0.69 (0.36 to 1.31)    0.16 (0.09 to 0.28)    0.30 (0.15 to 0.62)†   NA†                    0.28 (0.12 to 0.62)
   MSSA SSIs                          0.50 (0.37 to 0.69)             0.46 (0.29 to 0.72)†   0.56 (0.31 to 1.01)    0.50 (0.37 to 0.69)    0.61 (0.30 to 1.25)†   0.43 (0.29 to 0.62)†
  Glycopeptide prophylaxis studies:                                                                                                                               
   Gram positive SSIs                 0.70 (0.47 to 1.04)†            0.76 (0.49 to 1.18)†   0.69 (0.37 to 1.30)    0.62 (0.39 to 0.98)†   1.13 (0.90 to 1.42)    0.35 (0.12 to 1.03)†
   *S aureus* SSIs                    0.53 (0.24 to 1.16)†            0.52 (0.17 to 1.56)†   0.92 (0.59 to 1.44)    0.41 (0.20 to 0.84)    0.73 (0.33 to 1.63)    0.41 (0.10 to 1.64)†
   MRSA SSIs                          0.40 (0.20 to 0.80)             0.39 (0.15 to 1.03)    0.46 (0.13 to 1.63)†   0.32 (0.14 to 0.73)    0.65 (0.23 to 1.82)    0.22 (0.06 to 0.81)†
   MSSA SSIs                          1.47 (0.91 to 2.38)             1.32 (0.82 to 2.12)    1.18 (0.65 to 2.13)    0.81 (0.38 to 1.73)    1.01 (0.23 to 4.54)    1.48 (0.84 to 2.60)
  Bundle studies:                                                                                                                                                 
   Gram positive SSIs                 0.41 (0.30 to 0.56)             NA‡                    0.44 (0.31 to 0.65)    0.36 (0.24 to 0.53)    NA§                    0.41 (0.30 to 0.56)
   *S aureus* SSIs                    0.29 (0.19 to 0.42)             NA‡                    0.33 (0.21 to 0.52)    0.27 (0.15 to 0.47)    NA§                    0.29 (0.19 to 0.42)
   MRSA SSIs                          0.22 (0.12 to 0.38)             NA‡                    0.27 (0.14 to 0.53)    0.19 (0.10 to 0.38)    NA§                    0.22 (0.12 to 0.38)
   MSSA SSIs                          0.45 (0.26 to 0.78)             NA‡                    0.42 (0.23 to 0.77)    0.52 (0.27 to 1.01)    NA§                    0.45 (0.26 to 0.78)

SSIs=surgical site infections; MRSA=methicillin (meticillin) resistant *S aureus*; NA=not available; MSSA=methicillin susceptible *S aureus*.

\*Only three studies were not peer reviewed (two bundle studies and one glycopeptide prophylaxis study) thus results of non-peer reviewed studies could not be pooled.

†Studies are heterogeneous (P\<0.1) and results should be interpreted with caution.

‡Not enough studies to pool.

§No randomized controlled trials were performed for this intervention.

![**Fig 3** Forest plot of bundle intervention to prevent surgical site infections caused by Gram positive bacteria. All studies were observational](schm011382.f3_default){#fig3}

Nasal decolonization meta-analysis
----------------------------------

Of the 17 studies that assessed nasal decolonization, five were randomised controlled trials and 12 were quasi-experimental studies. Ten studies included cardiac operations and three assessed total joint arthroplasties. Since the number of studies that assessed total joint arthroplasty was small, we also included the seven studies that assessed nasal decolonization for general orthopedic operations. The decolonization regimen varied across studies. However, 16 of 17 studies used mupirocin ointment to decolonize the nares and one study used nasal chlorhexidine gluconate. (See supplementary table 1b for details of these studies.)

The meta-analysis of these 17 studies found that nasal decolonization was associated with a decreased rate of Gram positive surgical site infections and that these studies were significantly heterogeneous (fig 4[](#fig4){ref-type="fig"}). When surgical site infections caused by *S aureus* were assessed as the outcome among the 17 studies, the results were homogenous (I^2^=12%; P=0.32) and nasal decolonization was associated with a significantly lower risk of *S aureus* surgical site infections (table 2). The pooled relative risks were similar when study results were stratified by surgical site infections caused by MRSA or MSSA, suggesting decolonization was protective against either. Additionally, nasal decolonization was significantly protective against *S aureus* surgical site infections among patients who underwent orthopedic or cardiac surgical procedures (table 2). When only randomized controlled trials were assessed, nasal decolonization was associated with a statistically significant decline in *S aureus* surgical site infections, but this protective association was not statistically significant for all Gram positive surgical site infections (table 2).

![**Fig 4** Forest plot of nasal decolonization to prevent surgical site infections caused by Gram positive bacteria, stratified by study design](schm011382.f4_default){#fig4}

In 11 studies, all patients in the intervention group were decolonized with an intranasal antimicrobial agent regardless of whether they carried *S aureus* in their nares. When the effects of these studies were pooled, nasal decolonization was associated with a significant decrease in *S aureus* surgical site infections (pooled relative risk 0.40, 95% confidence interval 0.29 to 0.55). In contrast, six other studies decolonized only patients who carried *S aureus* in their nares. The pooled effect estimate of these six studies indicated that this approach was also associated with a significant decrease in *S aureus* surgical site infections (0.36, 0.22 to 0.57).

Six studies assessed nasal decolonization plus skin decontamination with either chlorhexidine gluconate or triclosan. The pooled effect estimate for this intervention was consistent with a protective effect against *S aureus* surgical site infections (0.29, 0.19 to 0.44). The meta-analysis of the 11 other studies, which assessed decolonization alone without skin decontamination, also found a statistically significant protective effect against *S aureus* surgical site infections (0.70, 0.50 to 0.97). However, none of the studies compared nasal decolonization alone with nasal decolonization plus skin decontamination.

Glycopeptide prophylaxis meta-analysis
--------------------------------------

Of the 15 studies assessing the effectiveness of preoperative glycopeptide prophylaxis, 12 assessed vancomycin and three assessed teicoplanin. Of the 15 studies, eight were randomised controlled trials, four were quasi-experimental studies, and three were retrospective cohort studies; eight studies included cardiac operations, five included total joint arthroplasties, and two assessed both. (See supplementary file table 1c for details of these studies.)

The meta-analysis of the association between glycopeptide prophylaxis and surgical site infections found that this intervention was significantly protective against MRSA surgical site infections compared with β lactam prophylaxis (table 2). Conversely, glycopeptide prophylaxis was a risk factor for MSSA surgical site infections, although this finding was not statistically significant (table 2). However, among all studies and among only randomized controlled trials, glycopeptide prophylaxis was not associated with significantly decreased surgical site infection rates caused by Gram positive bacteria or by *S aureus*(fig 5[](#fig5){ref-type="fig"}).

![**Fig 5** Forest plot of glycopeptide prophylaxis for all patients to prevent surgical site infections caused by Gram positive bacteria, stratified by study design](schm011382.f5_default){#fig5}

Six studies compared the efficacy of prophylaxis with a combination of a glycopeptide plus another antimicrobial agent (for example, rifampin, clindamycin, cefuroxime, cefazolin, ticarcillin/clavulante) and prophylaxis with a β lactam antibiotic only. When those six studies were pooled, the combination prophylaxis was significantly protective against Gram positive surgical site infections (pooled relative risk 0.22, 0.09 to 0.55). Conversely, when the nine studies that compared glycopeptide prophylaxis alone with β lactam prophylaxis were combined, glycopeptide prophylaxis was a risk factor for Gram positive surgical site infections, though this result did not reach statistical significance (1.19, 0.99 to 1.45).

Sensitivity analyses
--------------------

For each meta-analysis we calculated fixed effects relative risks and fixed effects risk differences. The fixed effects relative risks were nearly identical to the random effects relative risks for the associations between nasal decolonization and Gram positive surgical site infections (fixed effects 0.44, 0.36 to 0.54), between glycopeptide prophylaxis and Gram positive surgical site infections (fixed effects 0.89, 0.75 to 1.06), and between the bundle and Gram positive surgical site infections (fixed effects 0.40, 0.30 to 0.54). Nasal decolonization alone and the bundle were both associated with a significantly decreased risk of Gram positive surgical site infections (risk difference −0.0107, 95% confidence interval −0.0134 to −0.0080, and −0.0057, −0.0077 to −0.0038, respectively). Glycopeptide prophylaxis was not associated with a statistically significant decrease in the risk of Gram positive surgical site infections (−0.0036, −0.0088 to 0.0016).

Additionally, to evaluate whether interventions that focused on decreasing *S aureus* surgical site infections might increase the rate of surgical site infections caused by other organisms, we evaluated the studies to assess the association between the interventions of interest and all surgical site infections and surgical site infections specifically caused by Gram negative bacteria. Nasal decolonization was associated with a significantly protective effect of reducing all surgical site infections (pooled relative risk 0.60, 95% confidence interval 0.49 to 0.73) and Gram negative surgical site infections (0.15, 0.03 to 0.74). Compared with β lactam prophylaxis, glycopeptide prophylaxis was not statistically significantly associated with changes in all surgical site infections (1.00, 0.70 to 1.42) or Gram negative surgical site infections (0.90, 0.50 to 1.61).The bundle was significantly protective against all surgical site infections (0.47, 0.37 to 0.60) but was not significantly associated with changes in Gram negative surgical site infections (0.73, 0.39 to 1.36) nor Gram positive surgical site infections caused by pathogens other than*S aureus* (1.02, 0.50 to 2.05).

Publication bias assessment
---------------------------

Funnel plots assessing publication bias were visibly symmetrical for studies of nasal decolonization and studies of the decolonization and glycopeptide prophylaxis bundle (see supplementary figure 1). The funnel plot was visibly asymmetrical for studies of glycopeptide prophylaxis, suggesting that small studies that demonstrated the superiority of β lactam prophylaxis over glycopeptide prophylaxis may not have been published. However, if studies showing the superiority of β lactam prophylaxis were published, these studies would add further evidence that glycopeptide prophylaxis is not superior to β lactam prophylaxis for the prevention of surgical site infections.

Discussion
==========

Although multiple studies have assessed the efficacy of interventions to prevent surgical site infections caused by Gram positive bacteria, these interventions are not uniformly applied to surgical patients. Our results showed that nasal decolonization was associated with decreased rates of Gram positive surgical site infections and *Staphylococcus aureus* surgical site infections among patients undergoing cardiac or orthopedic surgical procedures. However, these results remained statistically significant for *S aureus* surgical site infections, though not all Gram positive surgical site infections, when the meta-analysis was limited to randomized controlled trials. Additionally, a bundle that included nasal decolonization and glycopeptide prophylaxis for patients who carried methicillin (meticillin) resistant *S aureus* (MRSA) was associated with significantly decreased rates of surgical site infections caused by Gram positive bacteria and by *S aureus*.

We also found that routine use of prophylactic glycopeptides protected against MRSA infections but not against all Gram positive surgical site infections. Additionally, dual prophylaxis with a glycopeptide and another antimicrobial agent seemed to be more protective against Gram positive surgical site infections than prophylaxis with glycopeptides alone. This finding is consistent with studies of methicillin susceptible *S aureus* (MSSA) bacteremia, which found that vancomycin is less effective than a β lactam antibiotic for treating MSSA infections.[@ref63] [@ref64] These results are similar to the conclusions of a recent review article, which stated that vancomycin is not recommended for preoperative prophylaxis but may be considered as a component of an MRSA bundle to prevent surgical site infections.[@ref65]

Our meta-analyses were the first to assess a bundle that included nasal decolonization and targeted glycopeptide prophylaxis for MRSA carriers. Other meta-analyses have assessed nasal decolonization or glycopeptide prophylaxis alone,[@ref66] [@ref67] [@ref68] and our results confirm the findings of the previous studies and extend these by including the results of recent studies. Future meta-analyses should assess other outcomes associated with these interventions. These outcomes could include duration of hospital stay since one group of researchers found that the mean duration of hospital stay was significantly shorter in those randomized to mupirocin and chorhexidine gluconate rather than to placebo.[@ref27] Future meta-analyses should also confirm our preliminary findings that these interventions do not open a niche for pathogens other than *S aureus* to fill, and should also analyze other patient populations such as those requiring trauma surgery to determine if these findings are generalizable to other surgical specialties.

Nasal decolonization protected against *S aureus* surgical site infections when all patients were decolonized and when only *S aureus* carriers were decolonized. Routine nasal decolonization of all surgical patients may be easier to implement and more cost effective than using cultures or polymerase chain reaction testing to screen patients preoperatively.[@ref69] None the less, it may be prudent to reserve mupirocin decolonization for patients who carry *S aureus* to prevent widespread mupirocin resistance.[@ref70] Similarly, it may be prudent to do further research on targeted prophylaxis with vancomycin before including this bundle in clinical practice. Of note, the pooled relative risks assessing Gram positive surgical site infections were identical for both the decolonization studies and the bundle studies. Thus high quality studies such as cluster randomized trials are still needed to determine whether adding glycopeptide prophylaxis to nasal decolonization will further decrease the incidence of Gram positive surgical site infections.

In our sensitivity analyses we found that nasal decolonization was associated with a 1% risk difference and the bundle was associated with a 0.5% risk difference in Gram positive surgical site infections. Although these differences seem small, they are clinically significant considering that cardiac and orthopedic operations are common and surgical site infections are associated with considerable morbidity. Each year, approximately 300 000 cardiac operations and approximately 900 000 total joint arthroplasties are done in the United States alone.[@ref71] Thus these interventions could prevent 6000 to 12 000 surgical site infections per year in the United States and even more worldwide.

Limitations of this study
-------------------------

Our study has some limitations. Firstly, meta-analyses are only as valid as the studies that contribute to the pooled risk ratio. We included many studies that were simple before and after quasi-experimental studies. Additionally, none of the included studies adjusted statistically for potential confounders, thus confounding may be problem, especially among the observational studies. To mitigate this limitation, we performed subset analyses on the results of only randomized controlled trials. Secondly, we did not include studies that did not report or could not provide specific data on Gram positive infections, thus we may have excluded important decolonization and prophylaxis studies. However, nine of 15 contacted investigators submitted additional data for inclusion in the analyses. Thirdly, studies of the association between interventions and Gram positive surgical site infections were heterogeneous, and thus some of the meta-analysis results should be interpreted with caution. Once these studies were stratified by potential sources of heterogeneity, the stratified subsets were homogeneous. For example, nasal decolonization aims to decrease the incidence of endogenous *S aureus* surgical site infections. The association between nasal decolonization and Gram positive surgical site infections may have been different for studies in which *S aureus* caused most Gram positive surgical site infections compared with studies in which surgical site infections due to other Gram positive pathogens were common. Thus we limited heterogeneity by doing subset analyses that separated studies focusing on *S aureus* surgical site infections from those focusing on all Gram positive surgical site infections.

Conclusion
----------

Surgical site infections caused by Gram positive bacteria may be prevented by decolonizing patients who carry *S aureus* in their nares and potentially by adding a glycopeptide to the usual prophylaxis using β lactam antibiotics for MRSA carriers. High quality randomized controlled trials or cluster randomized trials should be performed to further assess this bundle.

### What is already known on this topic

1.  Surgical site infections (SSIs) are potentially preventable adverse events of cardiac and orthopedic operations

2.  SSIs significantly increase hospital length of stay, readmission rates, healthcare costs, and mortality rates

3.  Clinicians and researchers have debated whether nasal decolonization or glycopeptide antibiotic prophylaxis reduce SSIs caused by Gram positive bacteria

### What this study adds

1.  Among patients undergoing cardiac or orthopedic surgery:

    1.  Nasal decolonization with mupirocin ointment was protective against Gram positive SSIs

    2.  Preoperative prophylaxis with anti-methicillin (meticillin) resistant *Staphylococcus aureus* (MRSA) antibiotics when given to all patients was not protective against Gram positive SSIs

    3.  A bundle that included nasal decolonization and anti-MRSA prophylaxis for MRSA carriers was significantly protective against Gram positive SSIs
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